866-997-4948(US-Canada Toll Free)

Venous Thromboembolism Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 59 Pages


GlobalData, the industry analysis specialist, has released its new report, “Venous Thromboembolism - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global VTE market. The report identifies the key trends shaping and driving the global VTE market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global VTE sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData estimates that the global Venous Thromboembolism (VTE) market was worth $3 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 5.7% for the next eight years, to reach $4.1 billion by 2017. This growth rate is primarily attributable to the strong current treatment options as well as strong pipeline candidates. This growth will be further supported by the high incidence rate of the disease, increased uptake of factor Xa inhibitor and direct thrombin inhibitor, and the launch of late-stage me-too candidates with improved efficacy and safety. 

Scope

The report provides information on the key drivers and challenges of the VTE market. Its scope includes:

  • Annualized global VTE market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Factor Xa Inhibitor, factor IXa inhibitor, factor VIII inhibitor, human antibody, VKOR inhibitor, active ß-d-thioxyloside, indirect thrombin inhibitor, direct thrombin inhibitor and ultra low molecular weight heparin.
  • Analysis of the current and future competition in the global VTE market. Key market players covered are Bristyol Myer Squibb, Pfizer Inc., Sanofi Aventis, Astellas Pharma Inc., Bayer Healthcare and Johnson and Johnson.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the VTE therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global VTE market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global VTE market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global VTE market landscape? - Identify, understand and capitalize
Table of Contents

1 Table of Contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Venous Thromboembolism: Introduction 6
2.1 Overview 6
2.2 GlobalData Pipeline Report Guidance 7

3 Venous Thromboembolism Market: Market Characterization 8
3.1 Overview 8
3.2 Venous Thromboembolism Market Size 8
3.3 Venous Thromboembolism Market Forecast and CAGR 9
3.4 Drivers and Barriers for the Venous Thromboembolism Market 11
3.4.1 Drivers for the Venous Thromboembolism Market 11
3.4.2 Barriers for the Venous Thromboembolism Market 11
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 13

4 Venous Thromboembolism Market: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profiles of the Major Marketed Products in the Venous Thromboembolism Market Heparin Class 15
4.3.1 Enoxaparin (Lovenox or Clexane) 15
4.3.2 Nadroparin (Fraxiparine) 16
4.3.3 Dalteparin (Fragmin) 17
4.3.4 Tinzaparin (Innohep) 18
4.4 Product Profiles of the Major Marketed Products in the Venous Thromboembolism Market Vitamin K Antagonist Class 19
4.4.1 Warfarin 19
4.5 Product Profiles of the Major Marketed Products in the Venous Thromboembolism Market Direct Thrombin Inhibitor Class 20
4.5.1 Lepirudin (Refludan) 20
4.5.2 Argatroban 21
4.5.3 Dabigatran Etexilate (Pradaxa) 21
4.5.4 Antithrombin Recombinant (ATryn) 22
4.6 Product Profiles of the Major Marketed Products in the Venous Thromboembolism Market Synthetic Pentasaccharide Class 23
4.6.1 Fondaparinux (Arixtra) 23
4.7 Product Profiles of the Major Marketed Products in the Venous Thromboembolism Market Thrombolytics Class 24
4.7.1 Alteplase 24
4.8 Key Takeaway 26

5 Venous Thromboembolism Market: Pipeline Assessment 27

5.1 Overview 27
5.2 Strategic Pipeline Assessment 27
5.2.1 Technology Trends Analytic Framework 27
5.3 Venous Thromboembolism Therapeutics Promising Drugs under Clinical Development 29
5.4 Molecule Profile for Promising Drugs under Clinical Development 30
5.4.1 Xarelto 30
5.4.2 Apixaban 31
5.4.3 YM150 32
5.5 Venous Thromboembolism Therapeutics Market Clinical Pipeline by Mechanism of Action 33
5.6 Venous Thromboembolism Pipeline Pipeline by Clinical Phases of Development 34
5.6.1 Venous Thromboembolism Therapeutics Regulatory Filing and Phase III Clinical Pipeline 35
5.6.2 Venous Thromboembolism Therapeutics Phase II Clinical Pipeline 36
5.6.3 Venous Thromboembolism Therapeutics Regulatory and Phase I Clinical Pipeline 36
5.6.4 Venous Thromboembolism Therapeutics Preclinical and Discovery Clinical Pipeline 36
5.7 Key Takeaway 36

6 Venous Thromboembolism Market: Implications for Future Market Competition 37

7 Venous Thromboembolism Market: Future Players in the Venous Thromboembolism Market 38

7.1 Introduction 38
7.2 Bristol-Myers Squibb Company 39
7.2.1 Company Overview 39
7.2.2 Business Description 39
7.2.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 40
7.2.4 Venous Thromboembolism Product Portfolio 40
7.3 Pfizer, Inc. 41
7.3.1 Company Overview 41
7.3.2 Business Description 41
7.3.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 43
7.3.4 Venous Thromboembolism Product Portfolio 43
7.4 Sanofi-Aventis 43
7.4.1 Company Overview 43
7.4.2 Business Description 44
7.4.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 44
7.4.4 Venous Thromboembolism Product Portfolio 45
7.5 Astellas Pharma, Inc. 46
7.5.1 Company Overview 46
7.5.2 Business Description 46
7.5.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 47
7.5.4 Venous Thromboembolism Product Portfolio 47
7.6 Bayer Healthcare 48
7.6.1 Company Overview 48
7.6.2 Business Description 48
7.6.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 49
7.6.4 Venous Thromboembolism Product Portfolio 49
7.7 Johnson & Johnson 50
7.7.1 Company Overview 50
7.7.2 Business Description 50
7.7.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 52
7.7.4 Venous Thromboembolism Product Portfolio 52

8 Venous Thromboembolism Market: Appendix 53
8.1 Market Definition 53
8.2 Abbreviations 53
8.3 Research Methodology 54
8.3.1 Coverage 54
8.3.2 Secondary Research 54
8.3.3 Forecasting 55
8.3.4 Primary Research 58
8.3.5 Expert Panels 58
8.4 Contact Us 58
8.5 Disclaimer 58
8.6 Sources 59

List of Table


Table 1: Venous Thromboembolism Therapeutics, Global, Revenue ($bn), 20012009 9
Table 2: Venous Thromboembolism Therapeutics, Global, Revenue Forecast ($bn), 20092017 10
Table 3: Major Marketed Products Comparison in the Venous Thromboembolism Therapeutics Market, 2010 25
Table 4: Venous Thromboembolism Therapeutics Most Promising Drugs under Clinical Development, 2010 29
Table 5: Venous Thromboembolism Therapeutics Phase III Clinical Pipeline, 2010 35
Table 6: Venous Thromboembolism Therapeutics Phase II Clinical Pipeline, 2010 36
Table 7: Venous Thromboembolism Therapeutics Phase I Clinical Pipeline, 2010 36
Table 8: Venous Thromboembolism Therapeutics Preclinical Pipeline, 2010 36
Table 9: Bristol-Myers Squibb Company Cardiovascular and Thrombosis Pipeline, 2010 40
Table 10: Pfizer Inc. Cardiovascular and Thrombosis Pipeline, 2010 43
Table 11: Sanofi-Aventis Cardiovascular and Thrombosis Pipeline, 2010 44
Table 12: Astellas Pharma Inc. Cardiovascular and Thrombosis Pipeline, 2010 47
Table 13: Bayer HealthCare Cardiovascular and Thrombosis Pipeline, 2010 49
Table 14: Johnson & Johnson Cardiovascular and Thrombosis Pipeline, 2010 52

List of Chart


Figure 1: Venous Thromboembolism Therapeutics, Global, Revenue ($bn), 20012009 9
Figure 2: Venous Thromboembolism Therapeutics, Global, Revenue Forecast ($bn), 20092017 10
Figure 3: Opportunity and Unmet Need in the Venous Thromboembolism Therapeutics Market 12
Figure 4: Strategic Competitor Assessment of the Marketed Products for Venous Thromboembolism, 2010 15
Figure 5: Technology Trends Analytic Framework of the Venous Thromboembolism Pipeline, 2010 28
Figure 6: Technology Trends Analytic Framework of the Venous Thromboembolism Pipeline Description, 2010 28
Figure 7: Venous Thromboembolism Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 33
Figure 8: Venous Thromboembolism Pipeline by Phase of Clinical Development, 2010 34
Figure 9: Implications for Future Market Competition in the Venous Thromboembolism Market, 2010 37
Figure 10: Venous Thromboembolism Therapeutics Market Clinical Pipeline by Company, 2010 38
Figure 12: GlobalData Market Forecasting Model 57

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *